WuXi AppTec, Inc. Selects H-Cube(R) from ThalesNano for Laboratory-based Hydrogenation

SHANGHAI, China, Dec. 23 /PRNewswire-Asia/ -- WuXi AppTec, the operating company of WuXi PharmaTech , a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced its selection of H-Cube(R) from ThalesNano Inc. for laboratory-based hydrogenation. WuXi thus joins all the top 20 pharmaceutical companies worldwide that have introduced and adopted the H-Cube technology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

"WuXi AppTec is one of the largest CRO companies in the world, providing the best services to pharmaceutical, biotechnology and medical device research and development industries. We are very glad to supply WuXi with our technique, best service and application," commented Dr. Urge, CEO of ThalesNano Zrt.

"We are very pleased for the employment of H-Cube, as Hydrogenation in flow for drug discovery is significantly a more productive and safer approach than traditional batch-based technique. We are looking forward to working with ThalesNano as we move to larger scale in the future," commented Shuhui Chen, Chief Scientific Officer of WuXi AppTec.

The H-Cube(R) Continuous-flow Hydrogenation Reactor is a bench-top standalone hydrogenation device, uniquely combining continuous-flow microchemistry with endogenous on-demand hydrogen generation and a disposable catalyst cartridge system. Compared to conventional methods, it allows safer, faster and more cost-efficient hydrogenation with superior yield. The H-Cube and the other novel Cube series flow reactor systems developed by ThalesNano Inc. are showing tremendous benefits in the drug discovery process including shortened development time, increased cost efficiency and reduced environmental impact.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

CONTACT: Sherry Shao of WuXi PharmaTech (Cayman) Inc., +86-21-5046-4002 or

Web site: http://www.wuxiapptec.com/

Back to news